prostate cancer
Conditions
Interventions
Sponsors
Department of Urology, Shanghai Changhai Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Male, aged <=85 years; 2. Patients who are planning to undergo prostate puncture for diagnosis due to elevated PSA, positive digital rectal examination, or suspected prostate cancer in imaging; 3. Patients who voluntarily participate in this trial after informing the existing diagnosis and treatment plan.
Exclusion criteria
Exclusion criteria: 1. Patients who have been diagnosed with any malignant tumor within the past 5 years; 2. Patients who have previously undergone transurethral resection or enucleation of the prostate; 3. Patients who have undergone prostate puncture due to suspected prostate cancer in the past; 4. Prostate cancer patients who have undergone distant metastasis have been judged by imaging; 5. Patients who have used anticoagulant and antiplatelet aggregation drugs for a long time (the anticoagulant has been stopped for less than 1 week); 6. Before joining the group, received any form of tumor treatment, including surgery, radiotherapy/chemotherapy, endocrine therapy, targeted therapy and immunotherapy; 7. At the same time suffering from other serious systemic diseases, which the investigator believes may interfere with the treatment, evaluation and compliance of this test, including severe respiratory, circulatory, neurological, mental, digestive, endocrine, immune, urinary and other systems disease; 8. Organ transplant subjects or people who have previously undergone non-autologous (allogeneic) bone marrow or stem cell transplantation; 9. Subjects who have undergone blood transfusion 1 month before blood draw; 10. Patients who are participating in other clinical trials, or have participated in other clinical trials and have been completed for less than one year; 11. Patients who are judged by the investigator to be unsuitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Whole-genome high-throughput sequencing of plasma cfDNA;Prostate biopsy results;Patients' clinical and biology information; | — |
Countries
China
Contacts
Public ContactRen Shancheng
Department of Urology, Shanghai Changhai Hospital
Outcome results
None listed